These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9798620)

  • 1. Daunorubicin cardiotoxicity in childhood cancer.
    Samuel L; Cummings J; Shaw P
    Lancet; 1998 Oct; 352(9134):1150. PubMed ID: 9798620
    [No Abstract]   [Full Text] [Related]  

  • 2. Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy.
    Lubieniecka JM; Liu J; Heffner D; Graham J; Reid R; Hogge D; Grigliatti TA; Riggs WK
    Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2118-20. PubMed ID: 23001242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
    Haruyama H; Shimazaki C; Nakanishi S; Hamami T; Nisio A; Isemura T; Katsume H; Nakagawa M; Ijichi H
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat.
    Cusack BJ; Young SP; Vestal RE; Olson RD
    Cancer Chemother Pharmacol; 1997; 39(6):505-12. PubMed ID: 9118462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: a 10-year experience.
    Sallan SE; Clavell LA
    Semin Oncol; 1984 Dec; 11(4 Suppl 3):19-21. PubMed ID: 6594762
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cardiotoxicity of anthracyclines. Apropos of 12 pediatric cases].
    Favrot MC; Pouyau G; Souillet G; Philip T; Bozzio A; Philippe N
    Pediatrie; 1981 Sep; 36(6):437-50. PubMed ID: 6947199
    [No Abstract]   [Full Text] [Related]  

  • 7. Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity?
    van den Berg MP; van Spaendonck-Zwarts KY; van Veldhuisen DJ; Gietema JA; Postma A; van Tintelen JP
    Eur J Heart Fail; 2010 Dec; 12(12):1297-9. PubMed ID: 20952769
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol.
    Hempel G; Relling MV; de Rossi G; Stary J; De Lorenzo P; Valsecchi MG; Barisone E; Boos J; Pieters R
    Pediatr Blood Cancer; 2010 Mar; 54(3):355-60. PubMed ID: 19731319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of 4-demethoxydaunorubicin toxicity (IMI 30). Preliminary data].
    Nobile MT; Pronzato P; Campora E; Ardizzoni A; Grimaldi A; Lionetto R; Repetto L; Rosso R
    G Ital Chemioter; 1985; 32(1):29-30. PubMed ID: 3913619
    [No Abstract]   [Full Text] [Related]  

  • 10. Unforeseen Severe Cardiotoxicity Associated With Daunorubicin Chemotherapy Even at a Dose Previously Thought to Be Safe: A Case Report.
    Juan MCY; Jones RT; Thabolingam RC
    Am J Ther; 2017; 24(4):e503-e504. PubMed ID: 27272204
    [No Abstract]   [Full Text] [Related]  

  • 11. [High-density lipoproteins as a form of daunorubicin transport in hepatoma cells of mice].
    Sumenkova DV; Poliakov LM; Panin LE
    Eksp Klin Farmakol; 2012; 75(5):32-4. PubMed ID: 22834127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of chromium(III) and manganese(II) as a potential protective approach against daunorubicin-induced cardiotoxicity: in vitro and in vivo experimental evidence.
    Liu Y; Wang D
    Biol Trace Elem Res; 2013 Dec; 156(1-3):253-61. PubMed ID: 24189981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anthracycline cardiotoxicity debate.
    Barber G
    Pediatrics; 1994 Nov; 94(5):778; author reply 781-2. PubMed ID: 7936922
    [No Abstract]   [Full Text] [Related]  

  • 14. Beneficial effects of angiotensin II receptor blocker, olmesartan, in limiting the cardiotoxic effect of daunorubicin in rats.
    Arozal W; Watanabe K; Veeraveedu PT; Thandavarayan RA; Harima M; Sukumaran V; Suzuki K; Tachikawa H; Kodama M; Aizawa Y
    Free Radic Res; 2010 Nov; 44(11):1369-77. PubMed ID: 20815778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anthracycline cardiotoxicity debate.
    Friedman DM
    Pediatrics; 1994 Nov; 94(5):778-9; author reply 781-2. PubMed ID: 7936923
    [No Abstract]   [Full Text] [Related]  

  • 16. The anthracycline cardiotoxicity debate.
    Finlay J; Meadows AT
    Pediatrics; 1994 Nov; 94(5):780-1; author reply 781-2. PubMed ID: 7936925
    [No Abstract]   [Full Text] [Related]  

  • 17. Echocardiographic assessment of anthracycline cardiotoxicity in children.
    Lewis AB; Pilkington R; Takahashi M; Siegel SE
    Med Pediatr Oncol; 1978; 5(1):167-75. PubMed ID: 745585
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical study of detorubicin. EORTC Clinical Screening Group.
    Recent Results Cancer Res; 1980; 74():184-91. PubMed ID: 7444139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiotoxicity in anthracycline chemotherapy: significance of infusion durations. Analysis of a Cochrane review].
    Appel JM; Rybjerg M; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3105-7. PubMed ID: 17877960
    [No Abstract]   [Full Text] [Related]  

  • 20. Anthracyclines: cardiotoxicity and its prevention.
    Hale JP; Lewis IJ
    Arch Dis Child; 1994 Nov; 71(5):457-62. PubMed ID: 7826122
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.